Sodium chloride

• The QP for the estimate is Ms. Terre Lane, MMSA, an employee of GRE and independent of Century.
• Metallurgical testing through 2020 focused on using sulfuric acid (H2SO4) to extract lithium from the clay.
• A lithium recovery of 78% is used in the Feasibility Study, based on the data collected in over two years of operations at the Pilot Pant.
• Contributors to the estimates are GRE (mining), Wood (process plant and infrastructure), ThyssenKrupp Nucera (chlor-alkali plant) and Century Lithium (property information and owners' costs).

• “We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.”
  Product launches within Baxter’s Pharmaceuticals portfolio in the U.S. include the following.
• For all products, please see full Indications, Important Risk Information and links to full Prescribing Information below.
• Baxter offers the first and only FDA-approved ready-to-use Norepinephrine in Dextrose, and now provides Norepinephrine in 4 mg/250 mL, 8 mg/250 mL and 16 mg/250 mL strengths.
• Baxter now offers Vancomycin in 500 mg/100 mL, 750 mg/150 mL, 1 g/200 mL, 1.25 g/250 mL and 1.5 g/300 mL strengths.

• 29 February 2024
  EMA/25090/2002 rev.23*
  Human Medicines Division

  Compilation of QRD decisions on stylistic matters in product information
  Issues
  Abbreviations

  Connected problems
  Subscript and superscript

  QRD Suggestions
  Acronyms must be written in their standard form; e.g.

• Cmax, Cmax
  Abbreviations and

  Not always understood,

  Non-standard abbreviations and acronyms should be avoided, and the term should be written out in full.

• The same applies when stating the pharmaceutical form in section 3 of the SmPC and section 4 of the labelling;
  i.e.
• critical steps prior to administration of the product should also be included (section 5 of Annex IIIA).
• Compilation of QRD decisions on stylistic matters in product information
  EMA/25090/2002

  Page 2/23

  Issues

  Connected problems

  QRD Suggestions

  emphasise in the labelling
  the special handling prior
  to administration of the
  product.

• Consistency

  Inconsistencies in style are

  Once a particular style or house style has been selected, it must be used consistently throughout the text.

• Tradename 150 mg solution for injection in pre-filled syringe
  Tradename 150 mg solution for injection in pre-filled pen

  information annexes?

• Compilation of QRD decisions on stylistic matters in product information
  EMA/25090/2002

  Page 3/23

  Issues
  Desiccant

  Connected problems

  QRD Suggestions

  For medicinal products

  The foil of blister packs containing a desiccant must be clearly labelled to show which blister pocket contains

  packaged with a desiccant

  the desiccant.

• For bottles containing a desiccant, a similar statement should also be considered provided there

  mistake the desiccant for a

  is available space.

• It can only be included in brackets in section 3 of the

  where can this be

  SmPC and section 4 of the labelling.

• Direct speech should only
  be used in section 6 of the SmPC for instructions about shelf-life, storage, handling and disposal.
• The term ?drug? though can be used in the product information annexes when it is part of a standard set of
  terms (e.g.
• Compilation of QRD decisions on stylistic matters in product information
  EMA/25090/2002

  Page 5/23

  Issues
  Foreign terms

  Connected problems

  QRD Suggestions

  Foreign terms, particularly

  Foreign terms must be written in italics; e.g.

• Patients can be referred to as ?he? or

  physician is often referred

  as ?she? when the medicinal product is exclusively for use by males or females.

• if the product in question might be

  measurements are

  used by elderly patients), in brackets after the metric measures in the English text.

• Compilation of QRD decisions on stylistic matters in product information
  EMA/25090/2002

  Page 6/23

  Issues

  Connected problems

  QRD Suggestions

  product name is composed
  of MAH+INN?

• Compilation of QRD decisions on stylistic matters in product information
  EMA/25090/2002

  Page 7/23

  Issues

  Connected problems

  QRD Suggestions
  MT: English
  BG: Bulgarian
  NL: Dutch
  CZ: Czech or English at applicant?s discretion.

• Compilation of QRD decisions on stylistic matters in product information
  EMA/25090/2002

  Page 14/23

  Issues

  Connected problems

  QRD Suggestions
  considered, e.g.

• Compilation of QRD decisions on stylistic matters in product information
  EMA/25090/2002

  Page 16/23

  Issues
  Symbols: Non-Unicode

  Connected problems

  QRD Suggestions

  The use of non-Unicode

  Only Unicode symbols must be used in submitted product information annexes.

• Compilation of QRD decisions on stylistic matters in product information
  EMA/25090/2002

  Page 20/23

  Issues

  Connected problems

  Units: SI base units -

  International Standard

  litre

  base units have been
  introduced in the European
  Union with Council
  Directive 80/181/EEC of
  20.12.79 (O.J.

• Compilation of QRD decisions on stylistic matters in product information
  EMA/25090/2002

  Page 23/23

• Excess salt (sodium) increases the risk of high blood pressure so everyone with hypertension is advised to reduce salt in their diet.
• It can be used just like regular salt and most people don’t notice any important difference in taste.
• Switching to potassium-enriched salt is feasible in a way that cutting salt intake is not.

What is potassium-enriched salt?

• Potassium-enriched salts replace some of the sodium chloride that makes up regular salt with potassium chloride.
• They’re also called low-sodium salt, potassium salt, heart salt, mineral salt, or sodium-reduced salt.

What is the evidence?

We have strong evidence from a randomised trial of 20,995 people that switching to potassium-enriched salt lowers blood pressure and reduces the risks of stroke, heart attacks and early death. The participants had a history of stroke or were 60 years of age or older and had high blood pressure.
An overview of 21 other studies suggests much of the world’s population could benefit from potassium-enriched salt. The World Health Organisation’s 2023 global report on hypertension highlighted potassium-enriched salt as an “affordable strategy” to reduce blood pressure and prevent cardiovascular events such as strokes.

What should clinical guidelines say?

• We teamed up with researchers from the United States, Australia, Japan, South Africa and India to review 32 clinical guidelines for managing high blood pressure across the world.
• While many guidelines recommend increasing dietary potassium intake, and all refer to reducing sodium intake, only two guidelines – the Chinese and European – recommend using potassium-enriched salt.

Why do so few people use it?

• Few people know a simple switch to potassium-enriched salt can help lower blood pressure and reduce the risk of a stroke and heart disease.
• Several Australian retailers stock potassium-enriched salt but there is usually only one brand available, and it is often on the bottom shelf or in a special food aisle.

A 2021 review found potassium-enriched salts were marketed in only 47 countries and those were mostly high-income countries. Prices ranged from the same as regular salt to almost 15 times greater. Even though generally more expensive, potassium-enriched salt has the potential to be highly cost effective for disease prevention.

Preventing harm

• People with serious kidney disease are already advised to avoid regular salt and to avoid foods high in potassium.
• No harm from potassium-enriched salt has been recorded in any trial done to date, but all studies were done in a clinical setting with specific guidance for people with kidney disease.
• In some countries, potassium-enriched salt is recommended to the entire community because the potential benefits are so large.

What will happen next?

• We are working with the taskforce to update Australian hypertension management guidelines, and to promote the new guidelines to health professionals.
• The next switch to iodised and potassium-enriched salt offers at least the same potential for global health gains.
• But we need to make it happen in a fraction of the time.

• Alta Schutte receives funding from the National Health and Medical Research Council of Australia, the Medical Research Future Fund, and NSW Health.
• She is Company Secretary of the Australian Cardiovascular Alliance, Board Member of Hypertension Australia, and Co-Chair of the National Hypertension Taskforce of Australia.